Current Price
Target Price
Analyst Sentiment
5 ratings: Buy
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. The company is headquartered in San Diego, California.
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
| Metric (B) | FY 2026 | FY 2026 | FY 2026 | FY 2027 |
|---|---|---|---|---|
| $-0.77 | $-0.90 | $-1.01 | $-3.95 | |
| 0 | 0 | 0 | 0 | |
| — | — | — | — |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | OOculis Hol... | OCSAW | — | — | — | — | — | — | — |
| 2. | PInternet P... | PTNT | — | — | — | — | — | — | — |
| 3. | PInternet P... | PTNT | — | — | — | — | — | — | — |
| 4. | RRocket Pha... | RCKTW | — | — | — | — | — | — | — |
| 5. | S60 Degrees | SXTPW | — | — | — | — | — | — | — |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Mar 25 | Jun 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 |
Gross Profit % | - | - | - | - |
| 11.45 | 14.1 | 22.11 | 24.67 | |
EBIT | -11.45 | -14.1 | -22.11 | -24.67 |
OPM % | - | - | - | - |
Non-Operating Income | 0.98 | 0.86 | 1.1 | 0.91 |
PBT | -10.48 | -13.24 | -21.01 | -23.76 |
Income Tax | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - |
Net Income | -10.48 | -13.24 | -21.01 | -23.76 |
NPM % | - | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2024 | Dec 2025 |
|---|---|---|
Revenue | 0 | 0 |
COGS | 0 | 0 |
Gross Profit | 0 | 0 |
Gross Profit % | - | - |
| 36.4 | 64.02 | |
EBIT | -36.4 | -64.02 |
OPM % | - | - |
Non-Operating Income | 5.71 | 3.47 |
PBT | -30.7 | -60.55 |
Income Tax | 0 | 0 |
Tax Rate % | - | - |
Net Income | -30.7 | -60.55 |
NPM % | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2024 | Dec 2025 |
|---|---|---|
| 100.15 | 136.68 | |
| 0 | 0 | |
| 0 | 0 | |
| 4.03 | 2.14 | |
| 2.6 | 24.14 | |
Total Assets | 106.78 | 162.97 |
| 0 | 0 | |
| -72.88 | -131.73 | |
| 0.53 | 22.4 | |
| 6.25 | 15.47 | |
| 172.88 | 256.82 | |
Total Liabilities | 106.78 | 162.97 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2024 | Dec 2025 |
|---|---|---|
| -31.42 | -46.92 | |
| -0.09 | -1.07 | |
| 17.56 | 84.53 | |
Net CFNet Cash Flow | -13.95 | 36.53 |
FCFFree Cash Flow | -31.51 | -47.99 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2024 | Dec 2025 |
|---|---|---|
| - | 59.2% | |
| -0.01 | -0.17 | |
| 15.38 | 8.97 | |
| - | 0.00 | |
Cash Conversion | 1.02 | 0.77 |
Payout Ratio | - | - |
| - | - | |
| - | - | |
| - | - | |
| 2.00 | 3.00 | |
| - | - | |
| - | - | |
| - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns BlossomHill Therapeutics Inc., from SEC filings
No SEC ownership filings for this company yet.
BlossomHill Therapeutics Inc.'s SEC filings and earnings call transcripts
No SEC filings for this company yet.
What recent news says about BlossomHill Therapeutics Inc., scored for sentiment.